With Intelligence Announces That Motive Partners Has Acquired a Majority Stake
20.7.2023 10:30:00 EEST | Business Wire | Press release
With Intelligence, a leading provider of investment data and intelligence for allocating, fund-raising and business development in the public and private markets, announced that it has received a majority investment from funds advised by Motive Partners (“Motive”), a specialist private equity firm focused on financial technology. Intermediate Capital Group ("ICG"), who originally invested in With Intelligence in 2020, will invest further alongside Motive. The investment is intended to serve as an accelerant for With Intelligence's growth, as the platform focuses on delivering leading connectivity, data and insights solutions to the Limited Partner and General Partner communities.
Founded in 1998, With Intelligence is a leading provider of data, intelligence and connectivity to the global asset management industry, with an integrated product suite of data, insights and events covering hedge funds, private credit, private equity, real estate and traditional asset management. Established 25 years ago, with over 500 employees and a geographic footprint across Europe, North America and Asia, With Intelligence has seen significant growth in recent years, with over 2,500 customers and a revenue compound annual growth rate of 33%.
With Intelligence blends data from a variety of the platform’s proprietary brands, delivering insights that include profiles, fund information, performance metrics and analyst perspectives. As the alternative investment landscape continues to evolve, With Intelligence is positioned to provide solutions that support mission-critical decision making across the fundraising and allocation lifecycle, for all participants in the value-chain. With Intelligence's strong growth is bolstered by a leading position in the hedge fund market, and is beginning to benefit from significant tailwinds driving the growth of private markets towards an estimated $15 trillion of assets under management in 2027.
Charlie Kerr, Founder & CEO at With Intelligence commented: “There is a huge opportunity for us to serve the global asset management industry during an exciting period of growth with greater data and analytics solutions than presently exist in the market. In order to capitalise on these tailwinds, we have chosen to partner with Motive Partners, who have a strong depth of expertise in financial technology across their group of Investors, Operators and Innovators. I am also grateful to ICG for their continued support and investment in the next phase of our growth journey.”
Neil Cochrane, Partner at Motive Partners commented: “We are positioned at the intersection of two exciting trends - the increase of allocations towards alternatives and the emergence of exciting new analytics and AI technologies to derive insights within the sector. Through the Motive IOI model and our extensive network, we are looking forward to capitalising on this market opportunity in partnership with Charlie, the With Intelligence team, and ICG.”
The investment by Motive and ICG will support With Intelligence to accelerate its data strategy and technology capabilities, continue to develop tailored offerings across various asset classes, grow the private markets offerings, and execute the next phase of the partnership and M&A strategies. It will also enable the company to further accelerate the pace of talent acquisition. Additionally, Motive's integrated operating model ("IOI model"), combining Investors, Operators and Innovators, will see a number of Motive team members collaborate with the With Intelligence team, including Charles Teschner (Industry Partner at Motive and the former CEO of Data and Analytics Solutions at BNY Mellon), Andy Stewart (Industry Partner at Motive, current CEO of Wilshire, and the former Co-Head of Blackrock's Alternative Investment Platform) and a team from Motive's innovation division, Motive Create.
“It has been a privilege to support the With Intelligence management team on their outstanding journey over the past few years, working alongside a visionary and entrepreneurial founder such as Charlie" said Jamie Rivers, Managing Director at ICG. Gareth Knight, Head of European Mid-Market at ICG added: "The company has a proven strategy for growth, and we're delighted to support the business for a further Investment cycle. We see Motive Partners being extremely well placed to help accelerate this over the coming years.”
Global investment banking firm Houlihan Lokey served as financial advisor to With Intelligence on the transaction, with other advisors including Proskauer (Legal), Financial & Tax (Alvarez & Marsal) and OC&C (Commercial). Arrowpoint Advisory, Joelson and Blick Rothenberg supported Management. Motive Partners' financial advisor was Raymond James, and they were also advised by MDW Capital Advisory (Debt Advisor), White & Case (Legal), Plural Strategy, Oliver Wyman (Commercial), and EY (Financial & Tax).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230720513739/en/
Contact information
With Intelligence
Louise Green, Chief Marketing Officer
louise.green@withintelligence.com
Motive Partners
Sam Tidswell-Norrish, Managing Director
sam@motivepartners.com
ICG
Clare Glynn, Head of Corporate Communications
clare.glynn@icgam.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
